Description
Detailed description is being prepared by our clinical team.
Clinical Trials
NCT07448116
Phase 1
Recruiting
Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.
China
NCT03155620
Phase 2
Active, not recruiting
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
United States, Australia, Canada, Puerto Rico